BlossomHill Therapeutics BLSM

Y. Peter Li, Ph.D., MBA Dr. Li is our cofounder and Executive Chairman and has served in these roles since the founding of our company in June 2020. Before BlossomHill, Dr. Li co-founded Turning Point Therapeutics, Inc. in October 2013. Dr. Li served as Turning Point's Chief Executive Officer and Chairman of its board of directors from October 2013 through October 2018, and as a member of its board of directors through April 2019. Prior to Turning Point, Dr. Li served in roles of increasing responsibility at Epitomics, Inc., an antibody technology company that was acquired by Abcam plc in March 2012, including as Executive Vice President. Dr. Li received his B.S. from the University of Science and Technology of China, his MBA from the Haas School of Business at the University of California, Berkeley, his Ph.D. in biochemistry from The Ohio State University and his postdoctoral training in molecular biology at the University of California, Berkeley.

Sundeep Agrawal, M.D. Dr. Agrawal has served as a member of our board of directors since December 2023. Dr. Agrawal is the Founder and Managing Partner of Brahma Capital, a biotechnology-focused investment firm he founded in February 2019. Previously, he was a General Partner at Colt Ventures, a U.S. based investment firm, from February 2019 to November 2024. Earlier in his career, Dr. Agrawal served as a Vice President at Longitude Capital, a healthcare investment firm, from July 2017 to December 2019, and as an Executive Director in Healthcare Investment Banking at Oppenheimer & Co., from September 2010 to May 2017. He has served on the board of directors of PAVmed Inc., a publicly held medical technology company, since September 2024, and previously served on the board of directors of FoxWayne Enterprises Acquisition Corp from January 2021 to January 2023. Dr. Agrawal received his B.A. in biology from George Washington University and his M.D. from the George Washington School of Medicine. He completed his clinical training at Lenox Hill Hospital in New York.

J. Jean Cui, Ph.D. Dr. Cui is our Scientific Founder, President, Chief Executive Officer and a member of our board of directors and has served in these roles since founding our company in June 2020. Prior to BlossomHill, Dr. Cui was the scientific founder of Turning Point Therapeutics, Inc. Dr. Cui served as Turning Point's Chief Scientific Officer and a member of its board of directors from October 2013 to June 2020. Prior to Turning Point, Dr. Cui was a Senior Principal Scientist and Associate Research Fellow at Pfizer. Prior to Pfizer, Dr. Cui served as Project Leader and Group Leader at Sugen, Inc., a Pharmacia Corporation. Dr. Cui received her B.S. and M.S. in chemistry from the University of Science and Technology of China, her Ph.D. in organic chemistry from The Ohio State University and her postdoctoral training in chemistry at Lawrence Berkeley National Laboratory and the University of California, Berkeley.

Jason Keyes, MBA Mr. Keyes has served as our Executive Vice President and Chief Financial Officer since May 2025. Prior to joining BlossomHill, Mr. Keyes served as the Chief Financial Officer of Equillium, Inc. from March 2018 through April 2025. From January 2013 through February 2018, Mr. Keyes served in various roles of increasing responsibility at Orexigen Therapeutics, Inc. (Orexigen), a publicly held pharmaceutical company, serving most recently as Executive Vice President and Chief Financial Officer. From August 2007 through January 2013, Mr. Keyes served in various financial leadership roles, including as Senior Director of Finance, at Amylin Pharmaceuticals, Inc., which was acquired by Bristol-Myers Squibb in 2012. Earlier in his career, Mr. Keyes also held leadership positions in finance and corporate strategy at Amgen Inc. and at Baxter Healthcare Corporation. Since August 2024, Mr. Keyes has served on the board of directors and as chair of the audit committee of Actuate Therapeutics, Inc. From February 2020 to March 2023, Mr. Keyes also served on the board of directors and as chair of the audit committee and member of the compensation committee of Sesen Bio, Inc. Mr. Keyes received his B.S. and M.S. in civil engineering from Stanford University and his MBA from the Anderson School at the University of California, Los Angeles.

John Schmid, MBA Mr. Schmid has served as a member of our board of directors since May 2026. Mr. Schmid has served as a member of the boards of directors of AnaptysBio, Inc., a publicly held biotechnology company (AnaptysBio), since June 2015, Design Therapeutics, Inc., a publicly held biopharmaceutical company, since November 2020, Bright Peak Therapeutics, Inc., a privately held biopharmaceutical company, since March 2025, Helix Acquisition Corp III, a special purpose acquisition company (Helix Acquisition Corp III), since January 2026, and First Tracks Biotherapeutics, Inc., a publicly held biopharmaceutical company, since April 2026 and following its spin out from AnaptysBio. Mr. Schmid serves as chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid previously served as a member of the board of directors of Xeris Pharmaceuticals, Inc. from September 2017 to June 2025, Poseida Therapeutics, Inc. from July 2018 until its acquisition by Roche in January 2025, Blacksmith Medicines (formerly known as Forge Therapeutics, Inc.) from May 2017 to April 2024, Neos Therapeutics LP from June 2015 until its acquisition by Aytu BioSciences, Inc. in March 2021, Helix Acquisition Corporation, a special purpose acquisition company, from October 2020 to April 2022 and Helix Acquisition Corporation II from February 2024 to August 2025. From September 2013 to June 2015, Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. until its sale to Teva Pharmaceutical Industries Ltd in May 2015. From June 2004 to September 2013, Mr. Schmid co-founded Trius Therapeutics, Inc. where he served as Chief Financial Officer until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid served as Chief Financial Officer of GeneFormatics, Inc. from 1998 until its acquisition by Cengent Therapeutics in May 2003. From 1995 to 1998, Mr. Schmid served as Chief Financial Officer of Endonetics Inc. Mr. Schmid received his B.A. in economics from Wesleyan University and his MBA from the University of San Diego.

Geoff Oxnard, M.D. Dr. Oxnard has served as our Executive Vice President and Chief Medical Officer since January 2025. Dr. Oxnard also has had a medical practice since April 2021, serving as a part-time thoracic oncologist at Boston Medical Center, a safety-net hospital in Boston. Prior to joining BlossomHill, Dr. Oxnard served as Vice President, Global Head of Thoracic Cancers at Eli Lilly & Co. from September 2023 through January 2025. From April 2021 through September 2023, Dr. Oxnard served as Senior Vice President, Head of Clinical Development at Foundation Medicine, a F. Hoffmann-La Roche AG company. Prior to joining Foundation Medicine, Dr. Oxnard spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School from 2011 through 2020 where his research focused on molecular drivers of sensitivity and resistance to precision cancer therapies and the application of molecular diagnostics to advance cancer care and drug development. Dr. Oxnard received his B.A. in chemistry from Harvard University and his M.D. from the University of Chicago-Pritzker School of Medicine. He completed his residency in internal medicine at Massachusetts General Hospital and completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Vincent Liptak, J.D., Ph.D., MBA Dr. Liptak has served as our Executive Vice President and General Counsel since April 2023. Prior to joining BlossomHill, Dr. Liptak was a partner at Barnes & Thornburg, LLP from June 2014 to October 2023 and also served as co-chair of the firm's Life Sciences Practice Group. Prior to Barnes & Thornburg, Dr. Liptak served as corporate counsel in the intellectual property division at Pfizer from 2009 to 2012, and as a Director of Licensing and Intellectual Property at HUYA Bioscience International LLC from 2013 to 2014. Prior to entering the legal profession, Dr. Liptak was a postdoctoral researcher in chemistry and neuroscience at the California Institute of Technology. Dr. Liptak received his B.S. in chemistry and mathematics from Loyola University Chicago, his M.S. from the University of Chicago, his MBA and J.D. from the University of San Diego and his Ph.D. from the University of Chicago

Bihua Chen, MBA Ms. Chen has served as a member of our board of directors since February 2021. Ms. Chen is the founder of Cormorant Asset Management, LP, an investment firm focused on innovative biotechnology, medical technology and life science companies, and has managed Cormorant's hedge fund as well as its private equity funds since its founding in February 2013. Prior to founding Cormorant, from 2005 to 2010, Ms. Chen served as a sub-adviser to Millennium Management LLC, a multi-strategy hedge fund. Previously, from 2001 to 2002, Ms. Chen was a healthcare analyst and sector portfolio manager for investment advisor American Express Asset Management. Ms. Chen also served as a portfolio manager for the Asterion Life Science Fund from 2001 to 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 to 2001 and an equity analyst for Putnam Investments from 1998 to 2001. Ms. Chen has served on the board of directors of Helix Acquisition Corp III, a publicly traded biotechnology special purpose acquisition company, since January 2026, and BridgeBio Oncology Therapeutics, Inc. since August 2025. Ms. Chen served on the board of directors of Biomea Fusion, Inc. from December 2020 to July 2025, Erasca, Inc. from March 2021 through August 2023, Helix Acquisition Corp II, a publicly traded biotechnology special purpose acquisition company that entered into a business combination with BridgeBio Oncology Therapeutics in August 2025, from January 2024 to August 2025, and Atea Pharmaceuticals, Inc. from June 2018 through October 2020. From August 2020 to April 2022, Ms. Chen served as the Chief Executive Officer and Chairman of the board of directors of Helix Acquisition Corp., a publicly traded biotechnology special purpose acquisition company that entered into a business combination with MoonLake Immunotherapeutics AG in April 2022. Ms. Chen received her B.S. in genetics and genetic engineering from Fudan University, Shanghai, China, her M.S. in molecular biology from the Weill Cornell Graduate School of Medical Sciences and her MBA from the Wharton School of the University of Pennsylvania.

Timothy Stubbs, M.D. Dr. Stubbs has served as a member of our board of directors since March 2024. Dr. Stubbs has served as an Executive Director at Vivo Capital LLC, a public and crossover biotech investment firm, since March 2022. Prior to Vivo, Dr. Stubbs was a Vice President at Morgan Stanley from March 2015 through March 2022. Prior to Morgan Stanley, Dr. Stubbs worked as a National Health Service physician in London, where he spent time in medical and surgical specialties, as well as the emergency room. Dr. Stubbs received his B.S. in anatomical science and MBChB from the University of Bristol, United Kingdom

Sheila Gujrathi, M.D. Dr. Gujrathi has served as a member of our board of directors since May 2026. Dr. Sheila Gujrathi is a seasoned biotech entrepreneur, physician executive, translational scientist, and drug developer. She has served as founder and Chief Executive Officer of Prana Therapies since March 2023, as founder and Executive Chair of the board of directors of Lila Biologics, Inc., a privately held biopharmaceutical company, since March 2023, as founder and Executive Chair of the board of directors of Vidya Therapeutics, Inc., a privately held biotechnology company, since March 2023, as a member of the board of directors of Janux Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2021, as Executive Chair of the board of directors of Ventyx Biosciences, Inc., a publicly held biopharmaceutical company, since May 2021, and as Executive Chair of the board of directors of Generian Pharmaceuticals, Inc., a privately held biotechnology company, since May 2023. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a privately held biopharmaceutical company, from June 2020 to January 2025, as Chair of the board of directors of ImmPACT Bio USA Inc., a privately held biotechnology company, from December 2021 until its acquisition by Lyell Immunopharma, Inc. in October 2024, as a member of the board of directors of Turning Point Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company in August 2022) (Turning Point), a then-publicly held biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors of Turning Point from April 2019 to March 2021. Dr. Gujrathi previously served as a member of the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen, Inc. in April 2021) from December 2015 to June 2019 and as a member of the board of directors of Ambrx, Inc., a then-publicly held biopharmaceutical company, from February 2014 until its acquisition by Johnson & Johnson in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a publicly held biopharmaceutical company, and served as its President and Chief Executive Officer from July 2018 to November 2020 and as its President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a then-publicly held biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Previously, Dr. Gujrathi worked at Bristol-Myers Squibb Company, where she served as Vice President of the Global Clinical Research Group in Immunology from August 2008 to June 2011. Prior, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from Oct 2002 to July 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in biomedical engineering and M.D. from Northwestern University. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.

Carl L. Gordon, Ph.D., CFA Dr. Gordon has served as a member of our board of directors since February 2021. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm, where he has served since January 1998. Dr. Gordon has served on the board of directors of Compass Therapeutics Inc., a publicly held biopharmaceutical company, since September 2015, and on the board of directors of Lomond Therapeutics Holdings, Inc., a privately held biotechnology company, since August 2024, as well as several other privately held companies. He previously served on the boards of directors of Adicet Bio, Inc. from August 2015 to April 2025, ArriVent BioPharma, Inc. from December 2022 to June 2025, Gemini Therapeutics Inc., from April 2016 until December 2022 (acquired by Disc Medicine, Inc.), Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 until November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 until February 2024 (acquired by Concentra Biosciences, LLC). Dr. Gordon earned a B.A. in chemistry from Harvard College, a Ph.D. in molecular biology from the Massachusetts Institute of Technology and was a Postdoctoral Fellow at the Rockefeller University.